TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Patients with metastatic breast cancer who have responded to a first line induction chemotherapy treatment.~* Age: at least 18 years old.~* Performance status Eastern Cooperative Oncology Group (ECOG) scale 0, 1, 2.~* Normal cardiac function, confirmed by left ventricular ejection fraction (LVEF).~* Hematology: leucocytes \>= 4 x 10\^9/l; neutrophils \>= 2.0 x 10\^9/l; platelets \>= 100 x 10\^9/l; hemoglobin \<= 10 g/dl.~* Hepatic function: total bilirubin \< 1 upper limit of normal (UNL); aspartate aminotransferase (ASAT) (SGOT) and alanine aminotransferase (ALAT) (SGPT) \< 2.5 UNL; alkaline phosphatase \< 5 UNL. Patients with ASAT (SGOT) and ALAT (SGPT) \> 1.5 UNL and alkaline phosphatase \> 2.5 UNL are not eligible.~* Renal function: creatinine \< 175 mmol/l (2 mg/dl); creatinine clearance \> 45 ml/min.~Exclusion Criteria:~* Pregnant or lactating patients.~* Previous cardiac dysfunction grade II or higher as per New York Heart Association, along with congestive cardiac failure.~* Hypersensitivity to anthracyclines or Cremophor®.~* Clinically significant hepatic dysfunction.~* Current uncontrolled infection.~* Mental confusion and lack of orientation.~* Any circumstance precluding an adequate follow-up.~* Radiotherapy in the previous 4 weeks.~* Any other concurrent neoplasm, except for basal cell carcinoma or in situ carcinoma.~* Symptomatic metastasis in the brain.~* Previous radiotherapy radiating a third of haematopoietic centres.~* Males.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: PLD (Type: EXPERIMENTAL): Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
- Arm B: Observation (Type: NO_INTERVENTION): Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* 18-50 years old~* Premenopause~* BMI ≥25~Exclusion Criteria:~* Cardiovascular disease~* Liver disease~* Gastrointestinal disease~* Kidney disease~* Diabetes mellitus~* Osteoporosis~* Pregnancy~* Lactation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Lactose (Type: PLACEBO_COMPARATOR): None
- Vitamin D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese chronic systolic heart failure patients with LVEF =\<30% by echocardiography and NYHA II or more~* Patients who receive standard therapy (Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blocker or diuretic)~Exclusion Criteria:~* Patients with a myocardial infarction, stroke, cardiac surgery or percutaneous coronary intervention within 30 days prior to randomization.~* Patients with serum potassium \>5.0 mmol/L or eGFR \<30 ml/min/1.73 m2.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eplerenone arm (Type: EXPERIMENTAL): Add on standard heart failure therapy
- Placebo arm (Type: PLACEBO_COMPARATOR): Add on standard heart failure therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Dry eye of moderate severity with ocular rosacea diagnosed by ophthalmologist. No contraindications of severe ocular surface disease or inability to be safely treated with IPL.~Dry eye symptoms must be alleviated with topical anesthetic. No GVHD, Stevens Johnson, active allergic conjunctivitis or other conjunctivitis, alkali burn history.~Subjects must have at least 50% meibomian glands viable on meibography and no new treatments for dry eye in the past 6 months.~Contact lenses and refractive surgery is okay.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- MGX and Intense Pulsed Light Treatment (IPL) (Type: EXPERIMENTAL): Treatment with 4 visits and 4 treatments of IPL and Meibomian Gland Expression (MGX)
- Meibomian Gland Expression (MGX) (Type: ACTIVE_COMPARATOR): Treatment with 4 visits and 4 treatments of MGX only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and/or female subjects between the ages of 18 and 55 years.~* Recreational polydrug user with a history of CNS depressant use.~Exclusion Criteria:~* History of clinically significant neurologic condition(s), such as seizures, convulsions, epilepsy, or significant head injury, as judged by the investigator or designee.~* A known history of hypersensitivity or previous intolerance to dimebon or other antihistamines.~* Self-reported history of drug or alcohol dependence (except nicotine or caffeine) in the 2 years prior to screening, or drug or alcohol dependence as defined by the (DSM-IV-TR) in 12 months prior to screening, including subjects who have ever been in a substance rehabilitation program (other than treatment for smoking cessation).~* History of clinically significant psychiatric disorder(s), as judged by the investigator or qualified designee.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- dimebon 20 mg (Type: EXPERIMENTAL): None
- dimebon 40 mg (Type: EXPERIMENTAL): None
- dimebon 60 mg (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None
- alprazolam 1 mg (Type: ACTIVE_COMPARATOR): None
- alprazolam 3 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.~* Subjects who met the requirements from previous adalimumab psoriasis study participation.~Exclusion Criteria:~* Subject considered by the Investigator, for any reason, to be an unsuitable candidate for the study.~* Female subject who was pregnant or breast-feeding or considering becoming pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosed CAD (either SVD or MVD) with signs or symptoms of myocardial ischemia, scheduled for percutaneous revascularization are all candidates.~* Either native vessels and SVG can be included with de-novo or recurrent lesions.~* Lesions causing a diameter stenosis \>50% in a main coronary artery (LAD, RCA, LCx) or their principal branches (Dg, OM, PL, PDA).~Exclusion Criteria:~* Diabetes~* Age over 80 years old~* Recent Q wave myocardial infarction (less than 2 weeks)~* Severe hypertension, uncontrolled despite medical treatment~* Gastric ulcer or symptomatic gastritis~* Neoplasia~* Renal failure (creatinine \>2.5)~* Left main disease, or left main equivalent (proximal LAD and proximal LCx), or three vessel disease involving the proximal segments of the 3 main coronary branches~* Suboptimal angiographic result of PCI (DS% \>30% or TIMI flow \<grade 3)~* Contraindications to high-doses of steroids (immunosuppression, active infective disease, osteoporosis, recent use of high doses of steroids).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: SHAM_COMPARATOR): Bare Metal Stenting
- 2 (Type: ACTIVE_COMPARATOR): Stenting with DES
- 3 (Type: EXPERIMENTAL): Bare metal stenting and administration of prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets protocol-specified criteria for qualification and contraception~* Is willing and able to comply with study procedures and restrictions related to food, drink and medications~* Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures~Exclusion Criteria:~* Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters~* Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:~  1. the safety or well-being of the participant or study staff;~ 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding);~ 3. the analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Debio 1143 (Type: EXPERIMENTAL): In addition to Cisplatin and Radiotherapy, Debio 1143 in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
- Placebo (Type: PLACEBO_COMPARATOR): In addition to Cisplatin and Radiotherapy, matching placebo in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have completed MOR-004~* Is willing and able to provide written, signed informed consent. Or in the case of patients under the age of 18 (or other age as defined by regional law or regulation), provide written assent (if required) and have written informed consent, signed by a legally authorize representative, after the nature of the study has been explained, and prior to performance of research-related procedures.~* If sexually active, must be willing to use an acceptable method of contraception while participating in the study.~* If female, of childbearing potential, must have a negative pregnancy test at Baseline and be willing to have additional pregnancy tests done during the study.~Exclusion Criteria:~* Is pregnant or breastfeeding, at Baseline, or planning to become pregnant (self or partner) at any time during the study.~* Has used any investigational product (other than BMN 110 in MOR-004), or investigational medical device, within 30 days prior to Baseline; or is required to use any investigational agent prior to completion of all scheduled study assessments.~* Was enrolled in a previous BMN 110 study, other than MOR-004.~* Has a concurrent disease or condition, including but not limited to, symptomatic cervical spine instability, clinically significant spinal cord compression, or severe cardiac disease that would interfere with study participation, or pose a safety risk, as determined by the Investigator.~* Has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMN 110 Weekly (Type: EXPERIMENTAL): BMN 110 Weekly: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
- BMN 110 Every Other Week (Type: EXPERIMENTAL): BMN 110 Every Other Week: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and will receive infusions of placebo on alternating weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, 3 years to \<18 years of age at baseline~* Positive HBsAg for more than 6 months~* Positive HBeAg and detectable HBV DNA at screening~* A liver biopsy obtained within the past 2 years prior to baseline (and more than 6 months after the end of previous therapy for hepatitis B) to confirm the presence of advanced fibrosis or exclude cirrhosis~* Compensated liver disease (Child-Pugh Class A)~* Elevated serum alanine transferase (ALT)~* Normal thyroid gland function at screening~Exclusion Criteria:~* Subjects with cirrhosis~* Subjects must not have received investigational drugs or licensed treatments with anti-HBV activity within 6 months of baseline. Subjects who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation in the study are also excluded~* Known hypersensitivity to peginterferon~* Positive test results at screening for hepatitis A, hepatitis C, hepatitis D or HIV infection~* History or evidence of medical condition associated with chronic liver disease other than chronic hepatitis B~* History or evidence of bleeding from esophageal varices~* Decompensated liver disease (e.g. ascites, Child-Pugh Class B or C)~* History of immunologically mediated disease~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- A Pegasys (Type: EXPERIMENTAL): None
- B Untreated Control (Type: NO_INTERVENTION): None
- C Fibrosis non-randomized (Type: EXPERIMENTAL): None
- Switch (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension From RCC Phase II (11515)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients are classified into two groups as below at transition date from Study 11515 to this study.~Population I: Patients who are willing to continue the study drug, for whom the investigator consider continuation of the study drug is appropriate, and who do not meet the criteria of removal from the study in Study 11515 at the end of Study 11515.~Population II: Patients who have been monitored only for survival status at the end of Study 11515.~Population 1~1. Patients who are willing to continue the study drug,~2. Patients for whom the investigator consider continuation of the study drug is appropriate~3. Patients who do not meet the criteria of removal from the study in Study 11515 at the end of Study 11515.~4. Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.~Population 2~1. Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.~Exclusion Criteria:~1. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results~2. Any condition that could jeopardize the safety of the patient or that affect his/her compliance in the study~3. Pregnant or breast-feeding patients. Both men and women enrolled in this trial must use adequate birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Nexavar, BAY43-9006) (Type: EXPERIMENTAL): Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using A Couple-focused Web-based Tailored Symptom Self-management Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Eligibility included men who:~* were diagnosed with localized PC;~* were within 16 weeks of completing their initial curative intent treatment \[26\] at genitourinary and radiation oncology clinics at two comprehensive cancer centers in the U.S southeast;~* were not treated for another cancer in last year; and~* had a partner \> 18 years of age not receiving cancer treatment.~Exclusion Criteria:~* Either member of couple unable to speak English~* Unwilling/unable to provide Informed Consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Survivorship Care Plan (SCP) (Type: PLACEBO_COMPARATOR): The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
- Enhanced SCP (ESCP) (Type: EXPERIMENTAL): ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Acute, untreated, hepatitis C infection, genotype 1 or 4, with an estimated duration less than 24 weeks~* Confirmed HIV-1 infection~* CD4 T cell count \>200/μL for individuals receiving antiretroviral therapy (ART), CD4 T cell count \> 500/μL at screening for individuals without ART~* Use of two effective contraception methods if female of childbearing potential or sexually active male with female partner~Key Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non HCV etiology~* Coinfection with hepatitis B virus (HBV)~* Treatment with any investigational drug or device within 60 days of the screening visit.~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF (Type: EXPERIMENTAL): LDV/SOF FDC for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete